Seismic Therapeutic Presents New Preclinical Data for S-4321, a Next Generation PD 1:FcγRIIb-Selective Bifunctional Agonist Antibody for the Treatment of Autoimmune Disease, at ACR Convergence 2024

Novel dual-cell bidirectional antibody engages two independent inhibitory receptors on multiple cell types in a single molecule

S-4321 is a low affinity PD-1 agonist with selective and functional FcγRIIb binding, without cell depleting activity

New preclinical data support differentiated profile, demonstrate induction of regulatory T cells and activity in a murine model of graft versus host disease

Company expects to initiate Phase 1 clinical trial of S-4321 in 1H 2025

Watertown, Mass., November 18, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new data for S-4321, its next generation PD‑1: FcγRIIb‑selective bifunctional agonist antibody for the treatment of autoimmune disease, at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, taking place in Washington, DC, on November 14-19, 2024. Based on the promising preclinical results, Seismic plans to initiate a Phase 1 clinical trial of S-4321 in healthy volunteers in the first half of 2025.

The presentation at ACR Convergence 2024 shows preclinical results supporting the mechanism of action of S-4321 and progress towards the clinic. S-4321 was designed using the Company’s IMPACT platform to agonize the inhibitory PD-1 receptor on T cells in the similar manner as its natural ligand, and to selectively bind and agonize the inhibitory FcγRIIb receptor on B cells/antigen presenting cells (APCs) without causing PD-1 expressing cell depletion.

Highlights of the poster presentation entitled, “S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease,” include:

Optimized Fab antibody domain with low affinity PD-1 binding achieved prolonged PD-1 agonism without causing PD-1 target depletion or IL-2 production, maintaining “the brakes” on activated T effector cells.
Machine learning-designed Fc antibody domain showed selective binding to the inhibitory FcγRIIb receptor over other FcγRs, avoiding the production of proinflammatory cytokines which may blunt efficacy and depletion of PD-1+ cells, including regulatory T cells (Tregs) which are needed for immune homeostasis. Moreover, the proprietary Fc domain in S-4321 agonizes FcγRIIb, adding B cell/APC inhibition in combination with PD-1 mediated T effector cell inhibition.
S-4321 promoted the induction of Tregs and inhibits graft versus host disease (GvHD) progression in a murine model.
Non-human primate studies demonstrated dose-proportional exposure and ~70% bioavailability of S-4321 with subcutaneous dosing, supporting the potential for a convenient self-administered regimen.

“We deliberately designed S-4321 as a novel bifunctional antibody with optimal agonism of both PD-1 and FcγRIIb inhibitory receptors in a single molecule,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “We believe the distinct profile of S-4321 will translate into superior drug activity and clinical benefit in a number of prevalent autoimmune diseases. We look forward to entering the clinic in healthy volunteers in the first half of 2025, where we will assess biomarkers of PD-1 agonist activity that are enabled by S‑4321’s differentiated mechanism.”

The poster for the data presented at ACR is available here on Seismic’s website.

At ACR Convergence 2024, Seismic also presented a poster on its second program preparing to initiate clinical development, S-1117, an engineered pan-IgG protease suitable for chronic administration, for the treatment of autoantibody-mediated diseases. The poster for the data presented at ACR is available here on Seismic’s website.

About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic to Participate in Upcoming Investor Conferences

Watertown, Mass., November 7, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that company management will participate in the following investor conferences:

Guggenheim’s Inaugural Healthcare Innovation Conference
Date: Wednesday, November 13, 2024
Location: Boston, MA
Format: Jo Viney, Ph.D., Founder, President and CEO, will be a speaker at the panel presentation titled, “Immunology & Inflammation: Cutting-Edge Technologies Driving the Next Wave of Biotech Breakthroughs”

Stifel Healthcare Conference 2024
Date: Tuesday, November 19, 2024
Location: New York, NY
Format: Company presentation and 1×1 meetings

Jefferies London Healthcare Conference
Date: Tuesday, November 19 – Thursday, November 21, 2024
Location: London, England, UK
Format: 1×1 meetings

Piper Sandler 36^th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Location: New York, NY
Format: Company presentation and 1×1 meetings

Wells Fargo Virtual Private Biotech Symposium
Date: Thursday, December 12, 2024
Location: Virtual
Format: 1×1 meetings

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Presents Data Demonstrating Key Capabilities and Broad Utility of Its Machine Learning-enabled IMPACT Platform to Create Novel Biologic Medicines

IMPACT platform deployed to design Company’s lead drug candidates, S-1117 and S-4321, which are on track to enter the clinic in 1H 2025

New data indicate platform’s potential to create additional novel biologics beyond pan-IgG proteases and agonist antibodies

Watertown, Mass., November 6, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of data supporting the broad ability of its IMPACT platform to create novel biologic medicines. The data show how the IMPACT platform was leveraged to design S-1117, an engineered pan-IgG protease suitable for chronic administration and one of the Company’s lead programs, and support its generalizability to create additional biologic modalities beyond pan-IgG proteases. These data on the enhanced capabilities of the IMPACT platform are being highlighted in an invited talk today at the 16^th PEGS Europe Protein and Antibody Engineering Summit (PEGS Europe 2024) in Barcelona, Spain.

Seismic’s IMPACT platform integrates machine learning with structural biology, protein engineering, and translational immunology for parallel, multi-property optimization of novel biologic therapies. The Company has built proprietary machine learning algorithms to simultaneously improve developability, modulate function, and minimize immunogenicity to enable the accelerated creation of biotherapeutics.

“We’re very excited to present new data on selected enhancements to Seismic’s IMPACT platform that demonstrate the benefits of integrating machine learning into the drug creation process to rapidly design and optimize novel drug-like protein therapeutics,” said Nathan Higginson-Scott, PhD, Chief Technology Officer at Seismic Therapeutic. “A key component of our approach is the ability to predict and remove both T and B cell epitopes beyond current state-of-the-art techniques, while maintaining other key attributes required to design biologic drugs.”

The oral presentation at PEGS Europe 2024 by Ryan Peckner, PhD, Director and Head of Machine Learning at Seismic Therapeutic, includes the following highlights:

Original application of the IMPACT platform, using a combination of in silico design and wet lab validation, to design S-1117, an engineered pan-IgG protease variant to reduce both T cell epitopes to prevent de novo anti-drug antibodies (ADA) generation and B cell epitopes to reduce pre-existing ADA binding and support chronic dosing, while retaining its activity and stability
New application of the IMPACT platform in which Seismic has shown the first example of engineering a protease’s specificity, applying the Company’s multi-objective optimization capabilities to create a selective IgE protease, using a combination of in silico design and wet lab validation, from a protease with both IgG and IgE cleaving properties in a single round of designs, while improving the activity and stability
In silico sequence design and fitness evaluation indicating that Seismic’s machine learning framework can, in a generalizable way, eliminate immunogenic T cell epitopes across a broad range of additional protein drug modalities, in particular non-protease enzymes and non-monoclonal antibodies, while maintaining their potency with high confidence

“Application of our IMPACT platform to new protein therapeutics for diseases of the immune system has enabled us to make rapid inroads into the design and development of our lead drug candidates – S-1117 , as well as S-4321, a dual-cell bidirectional PD-1 antibody agonist – that are on track to enter the clinic in the first half of 2025,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “These data show how we are strengthening our IMPACT platform to serve as our product engine, creating a range of biologic therapies designed to address diseases more effectively by optimizing for function, minimizing immunogenicity, and enhancing drug-like properties of biologic therapies.”

About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are created and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Announces Presentations at Upcoming Scientific and Medical Conferences

Watertown, Mass., November 5, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the company’s participation in four upcoming scientific and medical conferences, presenting on Seismic’s emerging pipeline of novel therapeutics to treat autoimmune and inflammatory diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.

Details of Seismic’s presentations and poster sessions are as follows:

IMPACT platform presentation:

November 5-7: PEGS Europe Protein & Antibody Engineering Summit, Barcelona, Spain

Presentation Title: Machine learning for multi-objective optimization of bacterial proteases that degrade pathogenic immunoglobulins
Session: Machine Learning Approaches for Protein Engineering: Part 1
Date: Wednesday, November 6
Time: 6:45 p.m. CET
Presenter: Ryan Peckner, PhD, Director, Head of Machine Learning

Pipeline program presentations:

November 14-19: American College of Rheumatology (ACR) Convergence, Washington, DC

Poster Title: Preclinical polypharmacology of S-1117, a novel engineered Fc-fused IgG degrading enzyme, for chronic treatment of autoantibody-mediated diseases
Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date: Saturday, November 16
Time: 10:30 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine

Poster Title: S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease
Session: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date: Monday, November 18
Time: 10:30 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine

December 7-10: American Society of Hematology (ASH) Annual Meeting, San Diego, CA

Poster Title: Preclinical polypharmacology of S-1117, a novel engineered Fc-fused IgG degrading enzyme, for chronic treatment of autoantibody-mediated diseases
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
Publication Number: 2562
Date: Sunday, December 8
Time: 6:00 p.m. PT
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine

December 15-19 – Antibody Engineering and Therapeutics Conference, San Diego, CA

Presentation Title: Dual Cell Bidirectional Antibodies for Treating Autoimmunity
Session: Main Conference
Date: Wednesday, December 18
Time: 11:00 a.m. PT
Presenter: Jyothsna Visweswaraiah, PhD, Director, Head of Biotherapeutics

In addition to the presentation, Dr. Visweswaraiah will serve as co-chair for the “Forward and reverse translation medicine” session on Monday, December 16 at 2:25 p.m. PT.

Poster Title: Engineering and development of an IgG degrading enzyme therapeutic using the IMPACT platform
Presenter: Allison Colthart, PhD, Principal Scientist Drug Creation

Poster Title: Discovery and Characterization an FcgRIIb-Selective PD-1 Agonist for the Treatment of Autoimmunity
Presenter: Colin Lipper, PhD, Senior Scientist, Drug Creation

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Presents New Preclinical Data on S-1117 in Autoantibody-Mediated Diseases Including Myasthenia Gravis at MGFA Scientific Session at AANEM Annual Meeting

Novel engineered Fc-fused pan-IgG protease demonstrates deep, rapid and sustained reduction of IgG levels and ability to address multiple pathogenic mechanisms as a single drug molecule

Preclinical data supports potential for S-1117’s multi-mechanistic action to address unmet need in myasthenia gravis

Company expects to initiate first-in-human Phase 1 clinical trial of S-1117 in 1H 2025

Watertown, Mass., October 15, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2024 annual meeting in Savannah, Georgia.

S-1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies that play a key role in the pathogenesis of a range of chronic and acute autoantibody mediated diseases, including myasthenia gravis (MG), a chronic neuromuscular autoimmune disorder. Seismic plans to initiate a Phase 1 clinical trial of S-1117 in healthy volunteers in the first half of 2025.

“S-1117 has shown the unique ability to target multiple orthogonal pathogenic mechanisms within a single molecule, and we believe this multi-mechanistic approach has the potential to drive deeper responses and offer improved clinical outcomes for MG patients, as well as for patients with other autoantibody-mediated diseases,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “Despite recent treatment advancements, there remains a significant opportunity to address the large proportion of MG patients who do not achieve remission or low disease activity with currently approved therapies. We believe S‑1117 can offer advantages over existing treatment options and look forward to advancing S‑1117 into first-in-human Phase 1 clinical studies in the first half of next year.”

The S-1117 preclinical data presented at AANEM showed deep, rapid and sustained reduction of all IgG subclasses. S-1117 also demonstrated the ability to directly cleave circulating and immune complexed IgG, as well as the IgG B cell receptor expressed on memory B cells. Moreover, current S-1117 PK/PD modeling indicates the potential for a convenient small volume, subcutaneous, self-administered treatment regimen administered every 4-6 weeks.

Highlights of the Presentation

In vitro, S-1117 was shown to cleave soluble forms of IgG from healthy volunteers and MG patients. The results support additional key attributes of S-1117:

Cleaves all IgG subclasses, including IgG3, in plasma of healthy individuals and MG patients;
Achieves a magnitude of soluble IgG cleavage in vitro from MG patients similar to healthy volunteers; and
Cleaves preformed immune complexes, which drive injury to tissues, as well as the B cell receptor.

In vivo studies performed with S-1117 in rabbit and mouse models showed rapid, deep and sustained IgG reduction and demonstrated cleavage of the B cell receptor within hours after both intravenous and subcutaneous administration.

Projections of human PK and PD through quantitative systems pharmacology (QSP) modeling for S-1117 indicate that infrequent chronic low doses can achieve titratable IgG reductions of 90% or greater. PK/PD modeling further supports the potential for a subcutaneous, self-administered treatment regimen to achieve therapeutic levels of IgG reduction at doses as low as <1mg/kg of drug administered monthly. In addition, given the rapid onset of action, S-1117 is predicted to be applied to acute conditions, such as MG crisis.

The poster for the data presented at AANEM is available here on Seismic’s website.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Announces Participation at Upcoming October Scientific and Medical Conferences

Watertown, Mass., September 30, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the company’s participation in three upcoming scientific and medical conferences, presenting on Seismic’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.

Details of Seismic’s presentations and poster sessions are as follows:

October 3-4: Biologics US, San Diego, CA
Presentation Title: Structure empowered IMPACT platform in the discovery & development of Immunoglobulin Sculpting (IgSc) enzyme & Dual-cell Bidirectional (DcB) antibody drugs for immunological diseases
Session: Track 1: Computational Tools, AI/ML-Guided Engineering
Date: Friday, October 4
Time: 2:15 p.m. PT
Presenter: Yi Xing, PhD, Senior Director, Head of Structural Biology

October 15-18: Myasthenia Gravis Foundation of America Scientific Session at American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, Savannah, GA
Presentation Title: Preclinical pharmacology of S-1117, a novel engineered Fc-fused IgG cleaving enzyme, for chronic treatment of autoantibody-mediated diseases including Myasthenia Gravis
Session: Therapeutics
Date: Tuesday, October 15
Time: 10:10 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine

October 15-18: CHI Immunogenicity & Bioassay Summit, Washington, DC
Presentation Title: Machine learning for deimmunization and multi-objective optimization of biologics
Session: Immunogenicity Prediction & Control – Deimmunization, Developability, and Machine Learning
Date: Friday, October 18
Time: 3:35 p.m. ET
Presenter: Ryan Peckner, PhD, Director, Head of Machine Learning

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Appoints Julie Eastland as Independent Board Director

WATERTOWN, Mass., September 23, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic’s Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology.

“It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization,” said Jo Viney, PhD, Co-founder, President and CEO of Seismic Therapeutic. “Julie’s wide range of leadership roles, experience with platform and asset-focused companies, and successful track record guiding biotechnology companies through significant organizational growth, and background spanning strategy, financial and operational perspectives will serve us well as we continue to mature our business and advance our first pipeline candidates into the clinic.”

“It is a privilege to join Seismic’s Board as the company continues to make a major shift in how immunology therapies are discovered and developed, enabled by machine learning,” said Julie Eastland. “I look forward to working with the accomplished team at Seismic as we build and advance a clinical pipeline of innovative enzyme and antibody drug programs to modulate the immune system in new and better ways. I believe Seismic’s approach has the potential to result in powerful, novel treatments for patients suffering from autoimmune diseases of high unmet need.”

Ms. Eastland most recently served as Chief Executive Officer and Board Director of Harpoon Therapeutics, formerly a publicly traded company (Nasdaq: HARP) focused on T-cell engager cancer immunotherapies, from November 2021 through its acquisition by Merck & Co in March of 2024. Prior to November 2021, she was a Harpoon Board Director and Chair of the Audit Committee from October 2018. Ms. Eastland has served in a variety of C-level executive roles for both private and public companies, including Chief Operating Officer/Chief Financial Officer for ReCode Therapeutics, a private company developing genetic medicines; Chief Financial Officer/Chief Business Officer for Rainier Therapeutics, a private company focused on FGFR3 in bladder cancer; Chief Financial Officer/Chief Business Officer for Cascadian Therapeutics, a public company (CASC) focused on Tukysa (tucantinib) in HER2+ breast cancer, through its acquisition by Seagen in 2018. Prior to Cascadian, Ms. Eastland served in a number of financial and strategic roles for VLST Corporation, focused on autoimmune and inflammation biology, Dendreon, an oncology cell therapy company marketing Provenge for prostate cancer, and Amgen.

Ms. Eastland currently serves as a Board member and audit chair at Dynavax Technologies (DVAX), board and audit committee member at Lantheus Holdings Inc (LNTH) and board member at Veana Therapeutics (private). Previously, she was a Board Director and Chair of the Audit Committee for Graybug Vision and Harpoon Therapeutics. She received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., August 26, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that company management will participate in the following investor conferences:

Morgan Stanley 22^nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Location: New York, NY
Format: Company presentation and 1×1 meetings

Cantor Global Healthcare Conference
Date: Tuesday, September 17, 2024
Location: New York, NY
Format: 1×1 meetings

Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Location: Virtual
Format: Company presentation and 1×1 meetings

10^th Annual World Medical Innovation Forum
Date: Wednesday, September 25, 2024
Location: Boston, MA
Format: Jo Viney, Ph.D., CEO, will be speaker at the panel presentation titled, “The Disruptors: The Role of Pathway Inhibition in Inflammation and Inflammatory Diseases”

BofA Healthcare Trailblazers Private Company Conference
Date: Wednesday, September 25, 2024
Location: Boston, MA
Format: 1×1 meetings

2024 RBC Capital Markets Biotechnology Private Company Virtual Conference
Date: Tuesday, October 1, 2024
Location: Virtual
Format: Company presentation and 1×1 meetings

Leerink Partners Biopharma Private Company Connect
Date: Wednesday, October 23, 2024
Location: Virtual
Format: 1×1 meetings

Media Contact

Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Appoints Brendan St. Amant as General Counsel

WATERTOWN, Mass., June 25, 2024 — Seismic Therapeutic, Inc., the machine learning immunology company, today announced the appointment of Brendan St. Amant as General Counsel and a member of the company’s leadership team. Mr. St. Amant brings more than 16 years of combined law firm and in-house experience across a range of areas, including corporate governance, securities and disclosure matters, regulatory and corporate compliance, business development and financing transactions, general business law, and managing legal and intellectual property functions at public and private biotechnology companies.

“We are delighted to welcome Brendan to the Seismic leadership team. He joins us at a time when we are rapidly evolving into a clinical-stage company, and his business skills and legal expertise will be highly valuable as we make progress toward important clinical and business milestones,” said Jo Viney, PhD, Co-Founder, President and CEO of Seismic. “Brendan has an outstanding track record as a business leader and legal expert, and his background at biotechnology companies is ideally suited to further strengthen our business excellence and help Seismic capture the tremendous opportunities ahead of us.”

“I am thrilled to join Seismic’s exceptional team and culture at a time when the company has such positive momentum in advancing its pipeline and business,” said Brendan St. Amant. “I look forward to collaborating with the leadership team to help Seismic achieve its goal of creating next generation immunology drugs for patients.”

Prior to joining Seismic, Brendan was General Counsel and Corporate Secretary for Synlogic, Inc., a publicly traded biotech company with a phase 3 clinical drug program. Previously, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was senior counsel at Vertex Pharmaceuticals. Brendan was a partner at the law firm of Donnelly, Conroy & Gelhaar, LLP, in Boston where he focused on complex commercial controversies and government enforcement. Earlier in his legal career, Brendan served as a clerk for the Hon. Alvin W. Thompson, Chief, U.S. District Court for the District of Connecticut and was an associate at the law firm of Goodwin Procter. Brendan has served on several practice-related bar committees and on the executive committee of the Board of Trustees of the Massachusetts Continuing Legal Education corporation. He received his BA from Cornell University, JD from Harvard Law School, and his MPP from the Harvard Kennedy School.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ (formerly known as Stern IR)
212-362-1200
emiley.demick@precisionaq.com

Seismic Therapeutic Announces Participation at Multiple Upcoming Scientific Conferences in June 2024

Data to Highlight Machine Learning IMPACT Platform and Emerging Pipeline of Novel Therapeutics to Treat Autoimmune Diseases

Watertown, Mass., June 4, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will participate in three upcoming scientific conferences, presenting data on Seismic’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery. The company’s two lead drug candidates will be highlighted: S-1117, a novel pan-immunoglobulin (Ig) G protease addressing multiple pathogenic mechanisms in autoimmune disease, and S-4321, a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional (DcB) antibody.

Details of Seismic’s presentations and poster sessions are as follows:

June 11-13 – Structure Based Drug Design Summit, Boston, MA

Presentation Title: Structure Empowered IMPACT Platform in the Discovery & Development of Immunoglobulin Sculpting (IgSc) Enzyme & Dual-Cell Bidirectional (DcB) Antibody Drugs for Immunological Diseases
Session: From Small Molecules to Peptides to Biologics: Dealing with Hard-to-Drug, Dynamic, Proteins with the Structural Biology Toolbox – Case Study Presentations
Date: Thursday, June 13
Time: 1:30 p.m. ET
Presenter: Yi Xing, PhD, Senior Director, Drug Creation

Poster Title: Structural Basis for Fc Domain Selectivity to FcgRIIB
Session: Afternoon Break & Poster Session
Date: Wednesday, June 12
Time: 3:00 p.m. ET
Presenter: Colin Lipper, PhD, Senior Scientist, Drug Creation

June 18-21 – Federation of Clinical Immunology Societies (FOCIS) 2024 Annual Meeting, San Francisco, CA

Poster Title: Identification and Characterization of PD-1 Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Date: Tuesday, June 18
Time: 6:00-7:30 p.m. PT
Poster #: #1735385; Tu131
Presenter: Mike Cianci, M.S. Senior Associate Scientist

Poster Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Date: Wednesday, June 19
Time: 1:00-5:00 p.m. PT
Poster #: #1735687; W121
Presenter: Ivan Mascanfroni, PhD, Senior Director, Immunology

June 23-26 – ESACT – European Society for Animal Cell Technology, Edinburgh, Scotland

Presentation Title: Mitigating Risk During Biologics Manufacturing Using Discovery Stage Developability Assays and State of the Art Machine Learning Based Optimization
Session: Session 2 – Transitioning from development to manufacture: How do science and innovation translate into highly efficient biomanufacturing?
Date: Wednesday, June 26
Time: 2:15-3:45 p.m. BST
Presenter: Jyothsna Visweswaraiah, PhD, Director, Drug Creation

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ (formerly known as Stern IR)
212-362-1200
emiley.demick@precisionaq.com